Method of targeting oncolytic viruses to tumors
AssigneesUniversity of South Florida, The United States Government as represented by the Department of Veterans Affairs
InventorsShyam S. Mohapatra, Subhra Mohapatra
Life of this patent
Estimating the term…
Abstract
The present invention pertains to a strategy of selectively targeting oncolytic virotherapy, using either naturally occurring or genetically modified viruses by packaging them in mesenchymal stem cells (MSCs). The present invention concerns MSCs, compositions comprising the MSCs, and methods of using the MSCs for treatment of cancer and for lysing or inducing apoptosis of cancer cells in vitro or in vivo.
Claims15
A mesenchymal stem cell (MSC) that is indoleamine 2,3-dioxygenase (IDO)-deficient due to CRISPR-mediated knockout of IDO and over-expresses interferon-beta.
Dependencies are inferred from the claim text.